JP2020531480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531480A5 JP2020531480A5 JP2020509479A JP2020509479A JP2020531480A5 JP 2020531480 A5 JP2020531480 A5 JP 2020531480A5 JP 2020509479 A JP2020509479 A JP 2020509479A JP 2020509479 A JP2020509479 A JP 2020509479A JP 2020531480 A5 JP2020531480 A5 JP 2020531480A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain sequence
- light chain
- heavy chain
- nicotine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 27
- 229960002715 nicotine Drugs 0.000 claims 27
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 27
- 239000012634 fragment Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545696P | 2017-08-15 | 2017-08-15 | |
| US62/545,696 | 2017-08-15 | ||
| PCT/US2018/046621 WO2019036419A1 (en) | 2017-08-15 | 2018-08-14 | NEW NICOTINE BINDING ANTIBODIES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531480A JP2020531480A (ja) | 2020-11-05 |
| JP2020531480A5 true JP2020531480A5 (enExample) | 2021-09-30 |
| JP7364555B2 JP7364555B2 (ja) | 2023-10-18 |
Family
ID=63405495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020509479A Active JP7364555B2 (ja) | 2017-08-15 | 2018-08-14 | 新規ニコチン結合抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11440970B2 (enExample) |
| EP (2) | EP4624496A3 (enExample) |
| JP (1) | JP7364555B2 (enExample) |
| KR (1) | KR102712005B1 (enExample) |
| CN (1) | CN111432883B (enExample) |
| AU (1) | AU2018317372B2 (enExample) |
| BR (1) | BR112020002994A2 (enExample) |
| CA (1) | CA3072767A1 (enExample) |
| ES (1) | ES3041362T3 (enExample) |
| MX (1) | MX2020001725A (enExample) |
| WO (1) | WO2019036419A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112512549A (zh) * | 2018-06-06 | 2021-03-16 | 安蒂多特疗法公司 | 改善循环和治疗心血管疾病的方法 |
| KR102530111B1 (ko) * | 2022-03-11 | 2023-05-10 | 앱클론(주) | 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0194158A3 (en) * | 1985-03-08 | 1988-02-24 | Baylor College of Medicine | Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays |
| US6232082B1 (en) | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2002251821A1 (en) | 2001-01-26 | 2002-08-06 | The Scripps Research Institute | Nicotine immunogens and antibodies and uses thereof |
| WO2003082329A2 (en) | 2002-03-01 | 2003-10-09 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US20060111271A1 (en) | 2004-11-24 | 2006-05-25 | Cerny Erich H | Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements |
| US8316104B2 (en) * | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| EP1963308A4 (en) | 2005-11-28 | 2010-12-15 | Nabi Biopharmaceuticals | METHOD FOR PRODUCING A NICOTINE HAPTEN |
| WO2007100755A1 (en) | 2006-02-27 | 2007-09-07 | Nabi Biopharmaceuticals | Method for decreasing the toxic effects of nicotine on fetuses in pregnant women |
| EP2222702B1 (en) * | 2007-11-29 | 2016-01-13 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| MX2010013583A (es) | 2008-06-13 | 2011-05-19 | Nabi Biopharmaceuticals | Kit y metodo para dejar de fumar. |
-
2018
- 2018-08-14 JP JP2020509479A patent/JP7364555B2/ja active Active
- 2018-08-14 MX MX2020001725A patent/MX2020001725A/es unknown
- 2018-08-14 CN CN201880067101.7A patent/CN111432883B/zh active Active
- 2018-08-14 EP EP25191604.5A patent/EP4624496A3/en active Pending
- 2018-08-14 AU AU2018317372A patent/AU2018317372B2/en active Active
- 2018-08-14 ES ES18760233T patent/ES3041362T3/es active Active
- 2018-08-14 BR BR112020002994-7A patent/BR112020002994A2/pt not_active Application Discontinuation
- 2018-08-14 EP EP18760233.9A patent/EP3668598B1/en active Active
- 2018-08-14 CA CA3072767A patent/CA3072767A1/en active Pending
- 2018-08-14 US US16/639,050 patent/US11440970B2/en active Active
- 2018-08-14 KR KR1020207007504A patent/KR102712005B1/ko active Active
- 2018-08-14 WO PCT/US2018/046621 patent/WO2019036419A1/en not_active Ceased
-
2022
- 2022-08-12 US US17/819,577 patent/US20230089068A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102947336B (zh) | 用dll4拮抗剂治疗糖尿病的方法 | |
| US9636334B2 (en) | Combination of lenalidomide and polypeptide construct, and uses thereof | |
| JP6148696B2 (ja) | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| JP2019511222A5 (enExample) | ||
| BRPI0922305B1 (pt) | Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos | |
| JP2019513726A5 (enExample) | ||
| CN104684552A (zh) | 组合及其用途 | |
| WO2015166112A1 (en) | Anti-human vegf antibodies with unusually strong binding afinity to human vegf-a and cross reactivity to human vegf-b | |
| JP2018529661A5 (enExample) | ||
| JP2021515003A (ja) | 体組成を変更するための方法 | |
| JP2020531480A5 (enExample) | ||
| JPWO2021163076A5 (enExample) | ||
| HK1179630B (en) | Methods of treating autoimmune diseases with dll4 antagonists | |
| HK1179630A (en) | Methods of treating autoimmune diseases with dll4 antagonists | |
| HK1179629A (en) | Methods of treating diabetes with dll4 antagonists | |
| HK1164165B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |